ProKidney Corp. (PROK) Financial Analysis & Valuation | Quarter Chart
ProKidney Corp. (PROK)
PROKPrice: $1.83
Fair Value: 🔒
🔒score
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to... more
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. ... more
Description
Shares
| Market Cap | $615.34M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Bruce Culleton |
| IPO Date | 2021-06-30 | CAGR | — |
| Employees | 204 | Website | www.prokidney.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PROK chart loading...
Fundamentals
Technicals
| Enterprise Value | $510.53M | P/E Ratio | -3.45 |
| Forward P/E | -3.18 | PEG Ratio | — |
| P/S Ratio | 820.06 | P/B Ratio | -0.14 |
| P/CF Ratio | -1.05 | P/FCF Ratio | -4.86 |
| EPS | $-0.53 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 190.52% | Gross Margin | -2.24% |
| Operating Margin | -189.6% | Profit Margin | -84.18% |
| ROE | 0.07% | ROA | -0.26% |
| ROCE | -0.63% | Current Ratio | 9.06 |
| Quick Ratio | 9.06 | Cash Ratio | 3.93 |
| Debt/Equity | -0 | Interest Coverage | -8871.16 |
| Altman Z Score | 5.31 | Piotroski Score | 1 |